...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy
【24h】

Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy

机译:重组新宫疾病病毒表达人追踪作为肝癌治疗的潜在候选者

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Newcastle disease-virus (NDV) have shown oncolytic therapeutic efficacy in preclinical studies and are currently proved for clinical trials. We have previously reported, for the first time, NDV Anhinga strain has an efficient cancer therapeutic efficacy in hepatoma. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a cytokine to selectively kill various cancer cells without toxicity to most normal cells. Numerous studies have demonstrated the potential use of recombinant soluble TRAIL as a cancer therapeutic agent. In this study, we have showed administration of a recombinant NDV Anhinga strain expressing soluble TRAIL (NDV/Anh-TRAIL) results in an efficient suppression of hepatocellular carcinoma without significant toxicity. The results show that recombinant NDV Anhinga strain expressing soluble TRAIL is a promising candidate for hepatoma therapy.
机译:Newcastle疾病病毒(NDV)在临床前研究中显示出溶解治疗效果,目前已证明临床试验。 我们以前报道,第一次NDV嗜毒菌菌株在肝癌中具有有效的癌症治疗效果。 肿瘤坏死因子相关的凋亡诱导配体(TRAIL)用作细胞因子,以选择性地将各种癌细胞与大多数正常细胞的毒性杀死。 许多研究表明,潜在使用重组可溶性痕迹作为癌症治疗剂。 在该研究中,我们表现出表达可溶性痕迹(NDV / Anh-Trave)的重组NDV嗜毒菌株的给药导致肝细胞癌的有效抑制而没有显着毒性。 结果表明,表达可溶性痕迹的重组NDV Anhinga菌株是肝癌治疗的有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号